Balaji Amines doubles profit, commissions India's first DME plant
Q1 net profit more than doubled to ₹78 cr as revenue rose 26% to ₹461 cr. The company also flagged completion of a 100,000 tpa dimethyl ether plant, a first for India.
— 1 earlier story on Balaji Amines Ltd. →What's new
- Revenue up 26% YoY to ₹461 crore; EBITDA margin expanded to 26% from 17%.
- India's first commercial-scale dimethyl ether plant commissioned at 100,000 tpa.
- N-methyl morpholine and acetonitrile expansions on track for FY27.
Why this matters
The earnings beat confirms Balaji Amines is riding a strong demand cycle in specialty chemicals. The DME plant opens a new revenue stream in an import-substitution market, and the subsidiary's ₹750 crore capex pipeline suggests management is betting the cycle has legs.
What we're watching
- Volume growth trajectory – 21,587 tonnes this quarter vs prior year.
- DME plant utilization and margin contribution over FY27.
- Balaji Speciality Chemicals capex milestones as brownfield/greenfield units come online.
The full read
A clean beat. Revenue hit ₹461 crore, up 26%; EBITDA more than doubled to ₹121 crore, pushing the margin from 17% to 26%. Net profit came in at ₹78 crore, more than double last year's ₹31 crore. The star move is the commissioning of India's first commercial-scale dimethyl ether plant at 100,000 tpa, adding a new product vertical in a market currently reliant on imports. The subsidiary's ₹750 crore capex plan is also tracking toward FY27 milestones, with both brownfield and greenfield units on schedule, pointing to sustained growth beyond the current quarter. The quarterly print confirms a healthy operating trajectory; the DME plant gives the narrative something more than just a cyclical upswing.
Questions answered
- What is the significance of the dimethyl ether plant?
- It is India's first commercial-scale DME plant, positioning Balaji Amines to capture import-substitution demand. DME can be used as an aerosol propellant, refrigerant, and fuel blend.
- How did margins improve so sharply?
- EBITDA margin rose to 26% from 17% on the back of higher volumes (21,587 tonnes) and likely better product mix. The company did not provide segment-level detail.
- When will the NMM and acetonitrile expansions be completed?
- The company says both projects are on track for commissioning during FY27. Exact timelines were not given.
- What is the current capex plan for Balaji Speciality Chemicals?
- The subsidiary has a ₹750 crore phased expansion programme, with brownfield and greenfield units targeted for FY27. Progress is described as 'on schedule'.
Balaji Amines Ltd.
Latest quarter · Jun 2026
Strength & growth
Story so far
All notes on BALAMINES →- 27 Jul 2026 · 7:30 PM IST Balaji Amines doubles profit, commissions India's first DME plant
- 1d ago Balaji Amines net profit surges 97% in Q1 FY27